JP2019142930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142930A5 JP2019142930A5 JP2019082794A JP2019082794A JP2019142930A5 JP 2019142930 A5 JP2019142930 A5 JP 2019142930A5 JP 2019082794 A JP2019082794 A JP 2019082794A JP 2019082794 A JP2019082794 A JP 2019082794A JP 2019142930 A5 JP2019142930 A5 JP 2019142930A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated
- pyridin
- trifluoromethyl
- amino
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013078 crystal Substances 0.000 claims 19
- 238000000634 powder X-ray diffraction Methods 0.000 claims 15
- URUBZXVIOILFLM-UHFFFAOYSA-N CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O Chemical compound CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O URUBZXVIOILFLM-UHFFFAOYSA-N 0.000 claims 12
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 6
- 201000005787 hematologic cancer Diseases 0.000 claims 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 6
- 230000000750 progressive effect Effects 0.000 claims 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 206010008583 Chloroma Diseases 0.000 claims 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000005987 myeloid sarcoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021123814A JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861884P | 2013-08-02 | 2013-08-02 | |
| US61/861,884 | 2013-08-02 | ||
| CNPCT/CN2013/081170 | 2013-08-09 | ||
| PCT/CN2013/081170 WO2015018060A1 (en) | 2013-08-09 | 2013-08-09 | Crystalline forms of therapeutically active compounds and use thereof |
| US201461939098P | 2014-02-12 | 2014-02-12 | |
| US61/939,098 | 2014-02-12 | ||
| US201461975448P | 2014-04-04 | 2014-04-04 | |
| US61/975,448 | 2014-04-04 | ||
| US201462011948P | 2014-06-13 | 2014-06-13 | |
| US62/011,948 | 2014-06-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531940A Division JP6742905B2 (ja) | 2013-08-02 | 2014-08-01 | 治療活性のある化合物及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021123814A Division JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019142930A JP2019142930A (ja) | 2019-08-29 |
| JP2019142930A5 true JP2019142930A5 (enExample) | 2019-10-10 |
Family
ID=52432592
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531940A Active JP6742905B2 (ja) | 2013-08-02 | 2014-08-01 | 治療活性のある化合物及びその使用方法 |
| JP2019082794A Withdrawn JP2019142930A (ja) | 2013-08-02 | 2019-04-24 | 治療活性のある化合物及びその使用方法 |
| JP2021123814A Pending JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531940A Active JP6742905B2 (ja) | 2013-08-02 | 2014-08-01 | 治療活性のある化合物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021123814A Pending JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9738625B2 (enExample) |
| EP (3) | EP3566706B1 (enExample) |
| JP (3) | JP6742905B2 (enExample) |
| CN (3) | CN110372670B (enExample) |
| AU (2) | AU2014295938B2 (enExample) |
| BR (1) | BR112016002287A2 (enExample) |
| CA (1) | CA2919382A1 (enExample) |
| CL (2) | CL2016000263A1 (enExample) |
| EA (1) | EA030428B1 (enExample) |
| ES (1) | ES2886211T3 (enExample) |
| IL (2) | IL243833A0 (enExample) |
| MX (2) | MX394658B (enExample) |
| MY (1) | MY177994A (enExample) |
| NI (1) | NI201600022A (enExample) |
| PE (1) | PE20160840A1 (enExample) |
| PH (1) | PH12016500164B1 (enExample) |
| SA (1) | SA516370523B1 (enExample) |
| SG (2) | SG11201600479WA (enExample) |
| TW (2) | TWI666208B (enExample) |
| UA (1) | UA121021C2 (enExample) |
| WO (1) | WO2015017821A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| KR20170057411A (ko) * | 2014-09-29 | 2017-05-24 | 아지오스 파마슈티컬스 아이엔씨. | 치료적 활성 화합물 및 이들의 사용 방법 |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107922354B (zh) * | 2015-05-07 | 2021-05-25 | 苏州韬略生物科技有限公司 | 作为idh2抑制剂的杂环化合物 |
| CN113307794A (zh) * | 2015-07-30 | 2021-08-27 | 正大天晴药业集团股份有限公司 | 1,3,5-三嗪衍生物及其使用方法 |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
| IL311873A (en) | 2015-10-15 | 2024-06-01 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| CA3002029A1 (en) * | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| AU2016340740B2 (en) * | 2015-10-21 | 2018-07-19 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof |
| CA3007363A1 (en) * | 2015-12-04 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Methods of treatment of malignancies |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| US10137130B2 (en) | 2016-02-26 | 2018-11-27 | Celgene Corporation | Methods of treatment of malignancies |
| WO2018026894A1 (en) | 2016-08-03 | 2018-02-08 | Celgene Corporation | Methods of treatment of myelodysplastic syndrome |
| JP7093764B2 (ja) * | 2016-08-03 | 2022-06-30 | セルジーン コーポレイション | 骨髄異形成症候群の治療方法 |
| EP3509570A1 (en) | 2016-09-07 | 2019-07-17 | Celgene Corporation | Tablet compositions |
| US11021464B2 (en) | 2017-01-22 | 2021-06-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine methanesulfonic acid salt |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| EP3644999B1 (en) | 2017-06-30 | 2022-12-14 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| KR20220101148A (ko) | 2019-11-14 | 2022-07-19 | 셀진 코포레이션 | 암의 치료를 위한 소아용 제제 |
| CN114773320A (zh) * | 2022-05-29 | 2022-07-22 | 重庆医科大学 | 1,3,5-三嗪化合物及其制备方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390529A (en) | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
| JPS58186682A (ja) | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
| DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
| EP0466647B1 (de) | 1990-07-12 | 1995-11-29 | Ciba-Geigy Ag | Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| US6274620B1 (en) | 1999-06-07 | 2001-08-14 | Biochem Pharma Inc. | Thiophene integrin inhibitors |
| WO2003037346A1 (en) * | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| SI2256108T1 (sl) | 2002-07-18 | 2016-05-31 | Janssen Pharmaceutica N.V. | Substituirani triazinski kinazni inhibitorji |
| US8258295B2 (en) * | 2007-04-30 | 2012-09-04 | Prometic Biosciences Inc. | Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| EP2440050A4 (en) * | 2009-06-08 | 2013-04-03 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION |
| US8486939B2 (en) * | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| KR101893112B1 (ko) * | 2012-01-06 | 2018-08-30 | 아지오스 파마슈티컬스 아이엔씨. | 치료학적으로 활성인 화합물 및 이의 이용 방법 |
| US20150011751A1 (en) | 2012-03-09 | 2015-01-08 | Carna Biosciences, Inc. | Novel triazine derivative |
| PE20160744A1 (es) | 2013-07-11 | 2016-08-01 | Agios Pharmaceuticals Inc | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| KR20170057411A (ko) * | 2014-09-29 | 2017-05-24 | 아지오스 파마슈티컬스 아이엔씨. | 치료적 활성 화합물 및 이들의 사용 방법 |
| WO2016126798A1 (en) | 2015-02-04 | 2016-08-11 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2014
- 2014-08-01 TW TW103126335A patent/TWI666208B/zh active
- 2014-08-01 MY MYPI2016700311A patent/MY177994A/en unknown
- 2014-08-01 PE PE2016000214A patent/PE20160840A1/es not_active Application Discontinuation
- 2014-08-01 TW TW108110624A patent/TWI701242B/zh active
- 2014-08-01 AU AU2014295938A patent/AU2014295938B2/en active Active
- 2014-08-01 SG SG11201600479WA patent/SG11201600479WA/en unknown
- 2014-08-01 EP EP19177845.5A patent/EP3566706B1/en active Active
- 2014-08-01 SG SG10201709187TA patent/SG10201709187TA/en unknown
- 2014-08-01 BR BR112016002287A patent/BR112016002287A2/pt not_active Application Discontinuation
- 2014-08-01 CN CN201910707312.9A patent/CN110372670B/zh active Active
- 2014-08-01 EP EP14832505.3A patent/EP3027193A4/en not_active Withdrawn
- 2014-08-01 MX MX2020011397A patent/MX394658B/es unknown
- 2014-08-01 EP EP21178745.2A patent/EP3932408A1/en not_active Withdrawn
- 2014-08-01 JP JP2016531940A patent/JP6742905B2/ja active Active
- 2014-08-01 UA UAA201601999A patent/UA121021C2/uk unknown
- 2014-08-01 ES ES19177845T patent/ES2886211T3/es active Active
- 2014-08-01 CA CA2919382A patent/CA2919382A1/en not_active Abandoned
- 2014-08-01 PH PH1/2016/500164A patent/PH12016500164B1/en unknown
- 2014-08-01 US US14/909,451 patent/US9738625B2/en active Active
- 2014-08-01 CN CN201480053796.5A patent/CN105916507A/zh active Pending
- 2014-08-01 MX MX2016001361A patent/MX389250B/es unknown
- 2014-08-01 CN CN201910708167.6A patent/CN110386922A/zh active Pending
- 2014-08-01 WO PCT/US2014/049469 patent/WO2015017821A2/en not_active Ceased
- 2014-08-01 EA EA201690322A patent/EA030428B1/ru not_active IP Right Cessation
-
2016
- 2016-01-28 IL IL243833A patent/IL243833A0/en unknown
- 2016-02-01 NI NI201600022A patent/NI201600022A/es unknown
- 2016-02-01 SA SA516370523A patent/SA516370523B1/ar unknown
- 2016-02-02 CL CL2016000263A patent/CL2016000263A1/es unknown
-
2017
- 2017-07-13 US US15/649,551 patent/US10093654B2/en active Active
- 2017-09-04 CL CL2017002240A patent/CL2017002240A1/es unknown
-
2018
- 2018-09-04 US US16/121,483 patent/US10730854B2/en active Active
- 2018-10-10 AU AU2018247242A patent/AU2018247242B2/en active Active
-
2019
- 2019-04-24 JP JP2019082794A patent/JP2019142930A/ja not_active Withdrawn
- 2019-10-31 IL IL270347A patent/IL270347B/en unknown
-
2020
- 2020-06-29 US US16/915,936 patent/US20210155603A1/en not_active Abandoned
-
2021
- 2021-07-29 JP JP2021123814A patent/JP2021176893A/ja active Pending
-
2023
- 2023-05-08 US US18/144,695 patent/US20240132474A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019142930A5 (enExample) | ||
| JP2019502669A5 (enExample) | ||
| RU2441005C2 (ru) | Новые пиразолопиримидины как ингибиторы циклинзависимых киназ | |
| JP2021098740A5 (enExample) | ||
| JP2018504429A5 (enExample) | ||
| JP2019513694A5 (enExample) | ||
| JP2020007311A5 (enExample) | ||
| JP7332293B2 (ja) | バルリチニブおよび抗癌剤を含んでなる併用療法 | |
| JP2018508512A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2019516733A5 (enExample) | ||
| JP2017008088A5 (enExample) | ||
| IL276948A (en) | N- (Cyanomethyl) -4– (2– (4-morpholinophenylamino) pyrimidine-4-il) salts Benzamide hydrochloride | |
| JP2020503247A5 (enExample) | ||
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| JP2020514311A5 (enExample) | ||
| JP2010520289A5 (enExample) | ||
| JP2012082234A5 (enExample) | ||
| JP2016533379A5 (enExample) | ||
| JP2014040437A5 (enExample) | ||
| JP2016527279A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| HRP20160361T1 (hr) | Terapija u kombinaciji s antitumorskim alkaloidom | |
| JP2016503399A5 (enExample) | ||
| JP2018534288A5 (enExample) |